Hangzhou Tigermed
Hangzhou Tigermed Consulting Co., Ltd., commonly known as Tigermed, is a leading clinical research organisation headquartered in Hangzhou, China. Founded in 2004, the company has established a strong presence across Asia, Europe, and North America, providing comprehensive services in the pharmaceutical and biotechnology sectors. Tigermed specialises in clinical trial management, regulatory affairs, and data management, offering unique solutions that streamline the drug development process. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous successful trials for global clients. Recognised for its expertise and reliability, Tigermed holds a prominent position in the industry, contributing to advancements in healthcare and supporting the development of new therapies. Its dedication to excellence has earned it a reputation as a trusted partner in clinical research.
DitchCarbon Score
How does Hangzhou Tigermed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hangzhou Tigermed's score of 39 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hangzhou Tigermed's reported carbon emissions
In 2024, Hangzhou Tigermed Consulting Co., Ltd. reported total greenhouse gas emissions of approximately 13,060,860 kg CO2e, comprising 116,820 kg CO2e from Scope 1 and 12,944,040 kg CO2e from Scope 2 emissions. This reflects a slight increase from 2023, where total emissions were about 13,850,210 kg CO2e, with Scope 1 at 118,730 kg CO2e and Scope 2 at 13,731,490 kg CO2e. The company has set ambitious reduction targets, aiming for a 15% decrease in both Scope 1 and Scope 2 emissions by 2025, relative to 2019 levels. Additionally, under the Science Based Targets initiative (SBTi), Tigermed has committed to reducing absolute Scope 1 and 2 emissions by 42% by 2030 from a 2023 baseline, and Scope 3 emissions by 25% within the same timeframe. These commitments position Hangzhou Tigermed as a proactive player in the pharmaceuticals, biotechnology, and life sciences sector, aligning with global climate goals to limit warming to 1.5°C. The company’s emissions data and reduction targets are independently verified and reflect its dedication to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 63,180 | 00,000 | 00,000 | 00,000 | 00,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 1,037,878 | 0,000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hangzhou Tigermed is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
